| Title | Bevacizumab plus oxaliplatin-based regimens for the treatment of colorectal cancer. |
| Author(s) | Scheithauer W, Schmiegel W |
| Institution | Division of Oncology, Department of Medicine I and Cancer Center, Medical University Vienna, Austria. werner.scheithauer@meduniwien.ac.at |
| Source | Onkologie 2009 Jul; 32(7):431-9. |
| Abstract | The anti-angiogenic, monoclonal antibody bevacizumab, in combination with chemotherapy, is proven to prolong survival in metastatic colorectal cancer. Recent data demonstrate that combining bevacizumab with widely used oxaliplatin-containing chemotherapy regimens is a promising strategy for further improving patient outcomes. |
| Language | eng |
| Pub Type(s) | Journal Article
Research Support, Non-U.S. Gov't
|
| PubMed ID | 19556824 |
